Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01753349 · ClinicalTrials.gov registry record

Phase IV-Cervical Dystonia-INTEREST IN CD2

A clinical trial, sponsored by Ipsen.

Completed
Registry status
1,050
Enrollment target

NCT01753349 is a clinical trial that has completed, run by Ipsen. The registered enrollment target is 1,050 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01753349 has completed, sponsored by Ipsen.

COMPLETED
Registry status
1,050 participants
Enrollment target

Study Summary

The purpose of the study is to document long-term response in real-life practice after injection cycles with BoNT-A in subjects suffering from idiopathic cervical dystonia (Long-term clinical and pharmaco-economic data).

Interventions

  • BIOLOGICAL Botulinum toxin type A

Trial Details

FieldValue
Enrollment Target 1,050 participants
Start Date 2012-12
Est. Completion 2017-09-25

Sponsor

Ipsen

85 total trials

What the Registry Record Tells You About NCT01753349

The ClinicalTrials.gov registry entry for NCT01753349 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,050 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Botulinum toxin type A is the first listed.

NCT01753349 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01753349 about?

NCT01753349 is a clinical study titled "Phase IV-Cervical Dystonia-INTEREST IN CD2". The purpose of the study is to document long-term response in real-life practice after injection cycles with BoNT-A in subjects suffering from idiopathic cervical dystonia (Long-term clinical and pharmaco-economic data).

What is the current status of trial NCT01753349?

This trial is currently completed. The enrollment target is 1,050 participants. The study started on 2012-12. Estimated completion is 2017-09-25.

What interventions are being tested in trial NCT01753349?

The interventions under investigation include: Botulinum toxin type A (BIOLOGICAL).

Who is sponsoring clinical trial NCT01753349?

This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.